QSAM Biosciences
Austin
About QSAM Biosciences
QSAM Biosciences is a developer of nuclear medicines for the treatment of cancer and related diseases and conditions. Its initial technology is Samarium-153 DOTMP, aka CycloSam, a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, leaders in the nuclear medicine space who also developed FDA-approved and commercially available Quadramet® (Samarium-153 EDTMP), indicated for pain palliation. CycloSam was assigned to IsoTherapeutics Group’s subsidiary, IGL Pharma, Inc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $200.0K
- Funding stage: M&A
- Last round: Debt Financing (May 2013)
- Website: qsambio.com
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/qsam-biosciences-2966591 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.